SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-036435
Filing Date
2023-05-04
Accepted
2023-05-04 16:30:16
Documents
13
Period of Report
2023-05-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea177985-8k_biondvax.htm   iXBRL 8-K 28983
  Complete submission text file 0001213900-23-036435.txt   252535

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bvxv-20230501.xsd EX-101.SCH 3745
3 XBRL DEFINITION FILE bvxv-20230501_def.xml EX-101.DEF 27120
4 XBRL LABEL FILE bvxv-20230501_lab.xml EX-101.LAB 37485
5 XBRL PRESENTATION FILE bvxv-20230501_pre.xml EX-101.PRE 25741
7 EXTRACTED XBRL INSTANCE DOCUMENT ea177985-8k_biondvax_htm.xml XML 5750
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37353 | Film No.: 23889251
SIC: 2836 Biological Products, (No Diagnostic Substances)